Centre for Policy on Ageing



A randomized, double-blind, placebo-controlled clinical trial of the Chinese herbal medicine "Ba Wei Di Huang Wan" in the treatment of dementia
Author(s)	Koh Iwasaki, Seiichi Kobayashi, Yuri Chimura
Journal title	Journal of the American Geriatrics Society, vol 52, no 9, September 2004
Pages	pp 1518-1521
Source	http://www.americangeriatrics.org http://www.blackwellpublishing.com
Keywords	Alternative medicine ; Dementia ; Evaluation ; Clinical surveys ; Japan.
Annotation	33 patients with mild to severe dementia (7 men, 26 women, mean age 84.4) from a long-term care facility in Japan were recruited to this 8-week randomised, double-blind, placebo-controlled trial. 16 patients were randomly assigned to the active drug, Ba Wei Di Huang Wan (BDW) and 17 to a placebo group. After the trial, cognitive function as assessed using the the Mini Mental State Examination (MMSE) significantly improved from 13.5 ±8.5 to 16.3 ±7.7 in the BDW group. The ADL score in the Barthel Index also changed significantly. In contrast, MMSE and Barthel Index scores for the placebo group showed no significant change. 8 weeks after the end of the administration, MMSE and Barthel Index scores of the BDW group declined to the baseline level. These results argue the benefits of BDW in the treatment of dementia. (RH).
Accession Number	CPA-041130237 A
Classmark	LK3: EA: 4C: 3G: 7DT
Data © Centre for Policy on Ageing

...from the Ageinfo database published by Centre for Policy on Ageing.